The herein presented PBPK model adequately describes the pharmacokinetics of LNG in healthy women.

In particular, the current whole-body PBPK model of LNG describes binding of LNG to albumin and SHBG, as well as metabolism by CYP3A4, and accurately captures the PK of LNG in plasma. 

